Peptidomimetic that targets PROHIBITIN on the vasculature of white adipose tissue, causing apoptosis of fat-supplying blood vessels and fat cell death.
Last Updated: May 2026
Adipotide is a synthetic peptidomimetic targeting PROHIBITIN on the vasculature of white adipose tissue, designed to induce apoptosis of fat-supplying blood vessels and consequent fat cell death. It is one of the earliest "vascular-targeting" approaches to obesity research. Development as a human therapeutic was halted due to nephrotoxicity signals in preclinical and early human work, but the compound remains a reference point in obesity research. Adipotide is not approved for any medical indication and is sold as a research-use-only material.
Adipotide is a peptidomimetic consisting of a peptide that binds PROHIBITIN — a marker overexpressed on the vasculature of white adipose tissue — linked to a pro-apoptotic peptide (KLAKLAK)2 that induces mitochondrial disruption and apoptosis specifically in the targeted endothelium. By killing the blood vessels supplying white adipose tissue, Adipotide produces fat tissue regression via vascular starvation rather than appetite suppression or metabolic modulation. Evidence level: Preclinical (rodent, non-human primate); Phase 1 human trial for prostate cancer.
In preclinical rodent and rhesus monkey studies, Adipotide produced substantial reductions in fat mass and body weight — up to 11% body weight reduction in obese monkeys over 4 weeks. A Phase 1 human trial in men with prostate cancer (Barnhart et al., Sci Transl Med, 2011) demonstrated proof-of-mechanism but raised renal toxicity concerns that halted further development for obesity. The renal signal was attributed to off-target peptide accumulation in kidney tissue. Evidence level: Preclinical (rodent + non-human primate); Phase 1 human (cancer indication, halted for obesity).
Adipotide's mechanism (vascular-targeted adipocyte apoptosis) is fundamentally different from GLP-1 agonism (appetite suppression and metabolic modulation) — Adipotide kills fat tissue physically, GLP-1 agonists reduce caloric intake. GLP-1 compounds have advanced to Phase 3 and FDA approval; Adipotide's clinical development for obesity was halted due to safety concerns. The compounds are not therapeutically comparable.
| Compound | Mechanism | Clinical status | Safety signal |
|---|---|---|---|
| Retatrutide | GLP-1 + GIP + glucagon | Phase 3 | GI events, dysesthesia |
| Tirzepatide | GLP-1 + GIP (dual) | FDA-approved | GI events |
| Adipotide | Vascular-targeted apoptosis | Halted for obesity | Renal toxicity |
The Phase 1 human trial in men with prostate cancer surfaced renal toxicity signals — proteinuria and elevated serum creatinine — attributed to off-target peptide accumulation in kidney tissue. This safety finding halted further development of Adipotide for non-life-threatening indications including obesity. Animal studies showed transient renal effects but the human signal was the development-stopping factor. Evidence level: Phase 1 human (cancer); renal safety signal documented.
Adipotide is not approved for any medical indication anywhere in the world as of May 2026. Clinical development for obesity was halted due to the renal safety signal in the Phase 1 trial. The compound remains available as research-use-only material from third-party laboratories. Buyers should be aware that Adipotide's development was discontinued specifically due to toxicity concerns — not due to lack of efficacy. Regulatory context in are peptides legal regulatory status by country.
Adipotide carries a documented renal toxicity signal from human trials that halted clinical development for obesity, making research-use protocols substantially riskier than for compounds whose safety signals are less established. Independent HPLC purity testing and mass spectrometry identity confirmation are essential but they don't address the underlying toxicity risk. Buyers considering Adipotide should be aware that the compound was specifically discontinued for human use due to safety, not abandoned for efficacy. Guidance in how-to-test-peptides hub.
Peptigrity purchases Adipotide vials anonymously at standard customer pricing, sends them to ISO-accredited third-party labs for HPLC and mass spectrometry analysis, and publishes the unedited certificate of analysis. The lab test table above this section shows the cross-shop dataset. Methodology in how we calculate trust scores.
Adipotide's Phase 1 human trial surfaced renal toxicity signals (proteinuria, elevated creatinine) attributed to off-target peptide accumulation in kidney tissue, leading the development program to halt further obesity trials. The decision reflected the unfavorable risk-benefit profile for a non-life-threatening indication.
Preclinical rodent and rhesus monkey studies showed substantial fat-mass reduction, and the Phase 1 human trial demonstrated proof-of-mechanism in prostate cancer patients — but the renal toxicity signal halted obesity-specific human trials before efficacy was clinically established for that indication.
Adipotide is legal to purchase as a research chemical for laboratory use in most jurisdictions, but it is not approved for human consumption and carries documented renal toxicity signals from human trials. Country breakdown in peptide legal status guide.
Independent third-party HPLC certificate of analysis from a lab the vendor does not own or pay, with mass spectrometry identity confirmation. Note that purity verification confirms what's in the vial — it does not address Adipotide's underlying toxicity risk profile. COA interpretation in red flags in peptide certificates of analysis.
No. Adipotide is not approved for human consumption, carries documented human-trial renal toxicity signals, and Peptigrity is an independent review platform, not a medical authority. Anyone considering Adipotide should be aware that clinical development for non-cancer indications was halted specifically for safety reasons. Consult a licensed physician.
Peptigrity does not make medical recommendations, but FDA-approved alternatives for weight management exist — semaglutide (Ozempic/Wegovy) and tirzepatide (Mounjaro/Zepbound) are FDA-approved through prescription and have established safety profiles. The investigational retatrutide is in late-stage development. These are not direct mechanism analogs to Adipotide but are evidence-based options for the weight-loss research question.
This section is for educational and informational purposes only and does not constitute medical advice. Adipotide is not approved by the FDA or any other regulator for human use and carries documented renal toxicity signals that halted its clinical development for obesity. Always consult a qualified healthcare provider before using any peptide or research compound. Peptigrity is an independent review platform and does not sell, endorse, or recommend specific products or vendors.
Real protocols and questions from members — independent of vendors, never sponsored.
Sign in to ask a question.
Every submitted test helps the community verify purity across brands. Free, fast, independent.